The market capitalization for Sarepta Therapeutics rocketed up billions of dollars after its gene therapy for a rare muscle disease showed early signs of safety, as well as an efficacy profile that some analysts described as beyond a home run.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,